A Study of Selumetinib in Chinese Paediatric and Adult Subjects with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Trial Identifier: D1346C00011
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
NCTID:: NCT04590235
Start Date: December 2020
Primary Completion Date: August 2022
Study Completion Date: August 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (Simplified) Translation

Trial Locations

Country Location
CN shanghai, CN, 200011
CN Shanghai, CN, CN-200092